These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 33030251)

  • 21. The impact of CD4+ CD25+ T cells in the tumor microenvironment of hepatocellular carcinoma.
    Lee WC; Wu TJ; Chou HS; Yu MC; Hsu PY; Hsu HY; Wang CC
    Surgery; 2012 Feb; 151(2):213-22. PubMed ID: 21975289
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Interleukin-7 enhances anti-tumor activity of CD8
    Teng D; Ding L; Cai B; Luo Q; Wang H
    Cytokine; 2019 Jun; 118():115-123. PubMed ID: 29655570
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Human CD14+ CTLA-4+ regulatory dendritic cells suppress T-cell response by cytotoxic T-lymphocyte antigen-4-dependent IL-10 and indoleamine-2,3-dioxygenase production in hepatocellular carcinoma.
    Han Y; Chen Z; Yang Y; Jiang Z; Gu Y; Liu Y; Lin C; Pan Z; Yu Y; Jiang M; Zhou W; Cao X
    Hepatology; 2014 Feb; 59(2):567-79. PubMed ID: 23960017
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Interleukin-24 Limits Tumor-Infiltrating T Helper 17 Cell Response in Patients with Hepatitis B Virus-Related Hepatocellular Carcinoma.
    Zhang M; Zhao H; Gao H
    Viral Immunol; 2022 Apr; 35(3):212-222. PubMed ID: 35099297
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibiting effect of Astragalus polysaccharides on the functions of CD4+CD25 highTreg cells in the tumor microenvironment of human hepatocellular carcinoma.
    Li Q; Bao JM; Li XL; Zhang T; Shen XH
    Chin Med J (Engl); 2012 Mar; 125(5):786-93. PubMed ID: 22490576
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Interleukin 22 is related to development and poor prognosis of hepatocellular carcinoma.
    Shi J; Wang Y; Wang F; Zhu Z; Gao Y; Zhang Q; Du Z
    Clin Res Hepatol Gastroenterol; 2020 Nov; 44(6):855-864. PubMed ID: 32205116
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Interferon-gamma produced by interleukin-12-activated tumor infiltrating CD8+T cells directly induces apoptosis of mouse hepatocellular carcinoma.
    Komita H; Homma S; Saotome H; Zeniya M; Ohno T; Toda G
    J Hepatol; 2006 Nov; 45(5):662-72. PubMed ID: 16935390
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunologic Features of Patients With Advanced Hepatocellular Carcinoma Before and During Sorafenib or Anti-programmed Death-1/Programmed Death-L1 Treatment.
    Macek Jilkova Z; Aspord C; Kurma K; Granon A; Sengel C; Sturm N; Marche PN; Decaens T
    Clin Transl Gastroenterol; 2019 Jul; 10(7):e00058. PubMed ID: 31295151
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Interleukin-35 suppresses the activity of natural killer-like B cells in patients with hepatocellular carcinoma.
    Liu S; Yang L; Jia S; Zhao R; Jin Z
    Int Immunopharmacol; 2021 Nov; 100():108161. PubMed ID: 34555643
    [TBL] [Abstract][Full Text] [Related]  

  • 30. LAIR1-mediated resistance of hepatocellular carcinoma cells to T cells through a GSK-3β/β-catenin/MYC/PD-L1 pathway.
    Pan B; Ke X; Qiu J; Ye D; Zhang Z; Zhang X; Luo Y; Yao Y; Wu X; Wang X; Tang N
    Cell Signal; 2024 Mar; 115():111039. PubMed ID: 38199599
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PD-1 expression is elevated in monocytes from hepatocellular carcinoma patients and contributes to CD8 T cell suppression.
    Yun J; Yu G; Hu P; Chao Y; Li X; Chen X; Wei Q; Wang J
    Immunol Res; 2020 Dec; 68(6):436-444. PubMed ID: 32975728
    [TBL] [Abstract][Full Text] [Related]  

  • 32. IL-33 Released in the Liver Inhibits Tumor Growth via Promotion of CD4
    Jin Z; Lei L; Lin D; Liu Y; Song Y; Gong H; Zhu Y; Mei Y; Hu B; Wu Y; Zhang G; Liu H
    J Immunol; 2018 Dec; 201(12):3770-3779. PubMed ID: 30446569
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Exogenous interleukin-33 promotes hepatocellular carcinoma growth by remodelling the tumour microenvironment.
    Wang W; Wu J; Ji M; Wu C
    J Transl Med; 2020 Dec; 18(1):477. PubMed ID: 33308251
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Blocking Tim-3 or/and PD-1 reverses dysfunction of tumor-infiltrating lymphocytes in HBV-related hepatocellular carcinoma.
    Liu F; Zeng G; Zhou S; He X; Sun N; Zhu X; Hu A
    Bull Cancer; 2018 May; 105(5):493-501. PubMed ID: 29576222
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Levels of chemokine receptors expressed on peripheral blood T lymphocytes of Egyptian patients with hepatocellular carcinoma.
    Allam MM; Abd El Moneim E; Hassouna MM; El Jaky A; Zaghlah H
    Egypt J Immunol; 2009; 16(1):17-25. PubMed ID: 20726319
    [TBL] [Abstract][Full Text] [Related]  

  • 36. NCR
    Liu Y; Song Y; Lin D; Lei L; Mei Y; Jin Z; Gong H; Zhu Y; Hu B; Zhang Y; Zhao L; Teo HY; Qiu J; Jiang W; Dong C; Wu D; Huang Y; Liu H
    EBioMedicine; 2019 Mar; 41():333-344. PubMed ID: 30827928
    [TBL] [Abstract][Full Text] [Related]  

  • 37. ATR inhibitor AZD6738 enhances the antitumor activity of radiotherapy and immune checkpoint inhibitors by potentiating the tumor immune microenvironment in hepatocellular carcinoma.
    Sheng H; Huang Y; Xiao Y; Zhu Z; Shen M; Zhou P; Guo Z; Wang J; Wang H; Dai W; Zhang W; Sun J; Cao C
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461345
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CXCR6 Inhibits Hepatocarcinogenesis by Promoting Natural Killer T- and CD4
    Mossanen JC; Kohlhepp M; Wehr A; Krenkel O; Liepelt A; Roeth AA; Möckel D; Heymann F; Lammers T; Gassler N; Hermann J; Jankowski J; Neumann UP; Luedde T; Trautwein C; Tacke F
    Gastroenterology; 2019 May; 156(6):1877-1889.e4. PubMed ID: 30710528
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interleukin-35 Suppresses Interleukin-9-Secreting CD4
    Zhang Q; Yang L; Liu S; Zhang M; Jin Z
    Front Immunol; 2021; 12():645835. PubMed ID: 34177894
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PD-1 and PD-L1 upregulation promotes CD8(+) T-cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients.
    Shi F; Shi M; Zeng Z; Qi RZ; Liu ZW; Zhang JY; Yang YP; Tien P; Wang FS
    Int J Cancer; 2011 Feb; 128(4):887-96. PubMed ID: 20473887
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.